Quantcast

Latest AbbVie Stories

2014-05-31 08:21:05

- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of...

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-27 12:30:25

Nationwide strategic health initiative aims to fill in knowledge gaps and connect patients and caregivers to local resources and one-on-one support NEW YORK, May 27, 2014 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) and AbbVie announced the launch of Partners in Parkinson's, a new strategic health initiative offering comprehensive support to help people with Parkinson's disease (PD) optimize their care at every stage of the disease. "No two cases of Parkinson's disease are...

2014-05-22 08:29:21

-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) -- Health Canada grants AbbVie's request for Priority Review MONTREAL, May 22, 2014 /CNW/ - AbbVie (NYSE: ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including...

2014-05-20 16:26:30

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA(®) (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical...

2014-05-20 08:32:20

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition of the session...

2014-05-16 23:09:18

The Long Island, New York law firm of Rudolph F. X. Migliore, P. C. has announced the Judicial Panel on MultiDistrict Litigation has scheduled a hearing session to consider consolidating lawsuits against AbbVie. Commack, New York (PRWEB) May 16, 2014 AbbVie, the makers of Androgel, allegedly made a defective medical product and hiding information about the defective drug Androgel, according to a number of federal lawsuits. The Judicial Panel on MultiDistrict Litigation has scheduled a...

2014-05-15 12:35:08

New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas NORTH CHICAGO, Ill., May 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline. Dr. Severino's...

2014-05-13 08:31:40

NORTH CHICAGO, Ill., May 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition...

2014-05-08 04:21:41

- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date1 NORTH CHICAGO, Ill., May 8, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The MAAs are supported by...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related